Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kate Lynn J Bill

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Cellular and Molecular Life Sciences : CMLS|May 14, 2016
Liposarcoma: molecular targets and therapeutic implicationsKate Lynn J Bill, Lucia Casadei, Bethany C Prudner, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|May 26, 2015
The hepatocyte growth factor receptor as a potential therapeutic target for dedifferentiated liposarcomaKate Lynn J Bill, Jeannine Garnett, Xiaoyan Ma, et al.
Plos One|July 23, 2015
HDAC8, A Potential Therapeutic Target for the Treatment of Malignant Peripheral Nerve Sheath Tumors (MPNST)Gonzalo Lopez, Kate Lynn J Bill, Hemant Kumar Bid, et al.
Cancer Cell International|July 10, 2018
miR-133a function in the pathogenesis of dedifferentiated liposarcomaPeter Y Yu, Gonzalo Lopez, Danielle Braggio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2015
SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated LiposarcomaKate Lynn J Bill, Jeannine Garnett, Isabelle Meaux, et al.
The Oncologist|April 26, 2019
Degree of <i>MDM2</i> Amplification Affects Clinical Outcomes in Dedifferentiated LiposarcomaKate Lynn J Bill, Nathan D Seligson, John L Hays, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Cellular and Molecular Life Sciences : CMLS|May 14, 2016
Liposarcoma: molecular targets and therapeutic implicationsKate Lynn J Bill, Lucia Casadei, Bethany C Prudner, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|May 26, 2015
The hepatocyte growth factor receptor as a potential therapeutic target for dedifferentiated liposarcomaKate Lynn J Bill, Jeannine Garnett, Xiaoyan Ma, et al.
Plos One|July 23, 2015
HDAC8, A Potential Therapeutic Target for the Treatment of Malignant Peripheral Nerve Sheath Tumors (MPNST)Gonzalo Lopez, Kate Lynn J Bill, Hemant Kumar Bid, et al.
Cancer Cell International|July 10, 2018
miR-133a function in the pathogenesis of dedifferentiated liposarcomaPeter Y Yu, Gonzalo Lopez, Danielle Braggio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2015
SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated LiposarcomaKate Lynn J Bill, Jeannine Garnett, Isabelle Meaux, et al.
The Oncologist|April 26, 2019
Degree of <i>MDM2</i> Amplification Affects Clinical Outcomes in Dedifferentiated LiposarcomaKate Lynn J Bill, Nathan D Seligson, John L Hays, et al.
Pageof 1